Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Exclusion Criteria

• •Have received corticosteroids within 3 months before starting the study for any symptoms.
• •Any other eosinophilic disorders.
• •History of clinical schistosomiasis, or having travelled within the preceding 6 months to an area with endemic schistosomiasis, including but not limited to Southeast and Southwest Asia, South America and Africa. Travel to these areas must not be planned for at least 6 months after the last dose.
• •Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing.
• •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
• •History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.